The widespread expression of CD47 in normal tissue means that a drug may need to be administered as a large initial dose and/or frequently to effectively block CD47 activity in cancer cells.[39] To overcome these limitations, the upstream regulators of CD47 in tumor cells need to be elucidated, and alternative treatments targeting these regulators may achieve a balance between antitumor efficacy and toxicity. Here, CD47 is linked to neoplasm.